Below are the most recent publications written about "Chemical and Drug Induced Liver Injury" by people in Profiles.
-
Day JW, Mendell JR, Mercuri E, Finkel RS, Strauss KA, Kleyn A, Tauscher-Wisniewski S, Tukov FF, Reyna SP, Chand DH. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Saf. 2021 10; 44(10):1109-1119.
-
Schneider KM, Elfers C, Ghallab A, Schneider CV, Galvez EJC, Mohs A, Gui W, Candels LS, Wirtz TH, Zuehlke S, Spiteller M, Myllys M, Roulet A, Ouzerdine A, Lelouvier B, Kilic K, Liao L, Nier A, Latz E, Bergheim I, Thaiss CA, Hengstler JG, Strowig T, Trautwein C. Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury. Cell Mol Gastroenterol Hepatol. 2021; 11(4):909-933.
-
Lu Y, Wu Y, Chen X, Yang X, Xiao H. Water extract of shepherd's purse prevents high-fructose induced-liver injury by regulating glucolipid metabolism and gut microbiota. Food Chem. 2021 Apr 16; 342:128536.
-
Dai J, Yang X, Yuan Y, Jia Y, Liu G, Lin N, Xiao H, Zhang L, Chen J. Toxicity, gut microbiota and metabolome effects after copper exposure during early life in SD rats. Toxicology. 2020 03 30; 433-434:152395.
-
Carreiro S, Marvel-Coen J, Lee R, Chapman B, Ambros V. Circulating microRNA Profiles in Acetaminophen Toxicity. J Med Toxicol. 2020 04; 16(2):177-187.
-
Khan FS, Akram M, Aslam N, Zaheer J, Mustafa SB, Kausar S, Khan AH, Khan IA, Munir N, Shah SMA, Tahir IM, Sharif A. Phytochemical analysis and hepatoprotective effect of polyherbal formulation on CCl4 induced hepatotoxicity in mice. Pak J Pharm Sci. 2018 Nov; 31(6 (Supplementary):2719-2723.
-
Iracheta-Vellve A, Szabo G. IL-1a in acetaminophen toxicity: a sterile danger signal. Cell Mol Immunol. 2018 Mar; 15(3):284-285.
-
Iracheta-Vellve A, Petrasek J, Gyongyosi B, Satishchandran A, Lowe P, Kodys K, Catalano D, Calenda CD, Kurt-Jones EA, Fitzgerald KA, Szabo G. Endoplasmic Reticulum Stress-induced Hepatocellular Death Pathways Mediate Liver Injury and Fibrosis via Stimulator of Interferon Genes. J Biol Chem. 2016 Dec 23; 291(52):26794-26805.
-
Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
-
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros?e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud? R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G?rl?v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May; 3(5):e217-27.